Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (313 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: acutehoursplacebointravenoussyndrome
  Phrases that lowered it: trialacidhistory orallergicphase iii
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 11.9% (raises risk) · Sponsor's track record
• Collaborators: 10 (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 59 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 13.3% (lowers risk) · Drug's FDA history
• Minimum age: 0.5 (lowers risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 17259 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 84361 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 177 (lowers risk) · Sponsor's track record
• Maximum age: 17 (raises risk) · Who can join
• Keywords listed: 6 (lowers risk) · Design
• Drug's FAERS reports marked serious: 79.2% (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Symptomatic Treatment of Acute Gastroenteritis NCT01257672 · started 2011 · scored riskier than 75% of active trials completed
• Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter NCT02028910 · started 2014 · scored riskier than 51% of active trials terminated
• Triage Administration of Ondansetron for Gastroenteritis in Children NCT03052361 · started 2017 · scored riskier than 77% of active trials terminated
• A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis NCT02699385 · started 2015 · scored riskier than 24% of active trials terminated
• BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis NCT02246439 · started 2014 · scored riskier than 26% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.